l c interview, page-50

• 
  

Sorry you had to sell out of IMU MM, I too have bought a house recently however have managed to hang onto my shares thus far. I am also building a business though and will need to sell shares to sell it, however IMU is one of the last holdings I will sell as I see the risk/reward for this company to be among the most favorable of any I own. 

As to your chemotherapy comment, I would have to say that a CR is rather unlikely from the chemotherapy alone. Don't forget how poor the prognosis is for the patients in our 1b trial: inclusion criteria from clinicaltrials.gov
 "metastatic gastricc or GEJ adenocarcinoma, or locally advanced disease not amenable to surgical resection"

The prognosis for these patients is extremely poor, with chemotherapy extending their lives on average by a matter of months: 
From: https://www.cancer.gov/types/stomach/hp/stomach-treatment-pdq#link/_73

"In the open-label, international phase III ToGA (Trastuzumab for Gastric Cancer [NCT01041404]) trial, patients with HER2-positive metastatic, inoperable locally advanced, or recurrent gastric or GE junction cancer were randomly assigned to chemotherapy with or without the anti-HER2 monoclonal antibody trastuzumab.

"Median OS was 13.8 months (95% CI, 12–16) in patients assigned to trastuzumab and 11.1 months (95% CI, 10–13) in patients assigned to chemotherapy alone (HR, 0.74; 95% CI, 0.60–0.91; P = .0046).[18][Level of evidence: 1iiA]"


So the chemotherapy patients survived from 10 to 13 months (median 11.1) and the chemotherapy plus trastuzumab (Herceptin - over $6BUSD in sales per year) survived between 12 and 16 months (median 13.8). Given that we have a patient with a complete response, and given that this patient had terminal gastric cancer, this appears to be pretty amazing. As I have mentioned previously this is not statistically significant at this stage and a bigger sample is required in order to prove that this result isn't an anomaly. Bloody exciting though! If we get similar results from a larger sample, we will have the new standard of care on our hands IMO